CANCER TEST
OVARIAN CANCER

HRD Score

Information

Questions

Turn Around Time:

HRD Score: 4 weeks*

* If the sample needs to be enriched to ensure successful results, we will contact you

ΘΕΛΩ ΤO TEST

I Choose HRD Score

Homologous Recombination Deficiency (HRD) is defined as the inability of a cell to repair damaged sections of its DNA, resulting in the formation of acquired chromosome breaks.

The HRD score is a molecular analysis approach to measure the cellular rate of acquisition of chromosomal breaks using specific quantitative standards (Loss of Heterozygosity –LOH, Telomeric Allelic Imbalance –TAI, Large Scale Transition –LST).

Στην Μικροδιαγνωστική, από την παραλαβή του δείγματος, την θέσπιση διάγνωσης μέχρι και την ολοκλήρωση του μοριακού προφίλ ενός ασθενή, η διαδικασία διέπεται από τις αρχές της διασφάλισης της Ποιότητας στην διεξαγωγή όλων των επιμέρους εξετάσεων.

What is the clinical utility of the HRD Score test?

HRD (i.e. genomic instability) testing may increase the
number of eligible patients, in addition to those carrying
mutations in the BRCA genes, who can receive targeted therapy.

Tumors with elevated HRD values (positive HRD score) have been shown to be more sensitive to platinum regimens as well as to poly(ADP) ribose polymerase inhibitors (PARP inhibitors).

What sample is needed and how is the HRD Score performed at Microdiagnostics?

The tests are performed on the surgical specimen (paraffin cubes) or the biopsy material (paraffin cube) from which your histological examination was performed or on the aspiration material (FNAB, EBUS) from which your cytological examination was performed. In our fully integrated Laboratory, the pathologist selects the most appropriate & representative paraffin cube, ensuring that the most appropriate sample will be used for the tests. Qualitative and quantitative parameters are checked.

In case your sample is not already at Microdiagnostics archive, please contact us immediately so that we can arrange for its safe and rapid transport to our laboratory. You will also need to quickly and easily complete the Consent Form.

One touch approach – Strategic sample management, Time saving

In our fully integrated Laboratory, we handle your sample in such a way as to minimize its unnecessary waste:

The paraffin cube is placed, if possible, once on the microtome for obtaining tissue sections, by experienced tissue technologists.
Tissue sections are obtained sequentially in such a way as to ensure diagnosis and perform Immunohistochemistry if required.
Ensuring preservation of tissue sections for further molecular testing.
Pathologists perform microdissection to ensure the maximum amount of cancer cells possible, removing all other necrotic cells or normal tissue that could affect the validity of the results.
The molecular biologist immediately processes the tissue in a fully controlled environment, using next-generation sequencing (NGS) or real-time polymerase chain reaction (Real-time PCR) to identify mutations in the genes of interest.

Frequently Asked Questions (FAQ)

How will the HRD Score test help me?

HRD (i.e. genomic instability) testing may increase the number of eligible patients, in addition to those carrying mutations in the BRCA genes, who can receive targeted therapy.

Tumors with elevated HRD values (positive HRD score) have been shown to be more sensitive to platinum regimens as well as to poly(ADP) ribose polymerase inhibitors (PARP inhibitors).

NCCN guidelines: Ovarian cancer. V1.2020

What sample is required for the HRD score test?

Can the tests be performed on my sample?

Most of the time, the sample material we are called upon to handle is small because it has resulted from a minimally invasive method (needle biopsy, fluid aspiration, paraffin block with minimal material).

In our laboratory, Pathologists check in a timely manner whether the material to be examined is sufficient. If so, then a management algorithm is followed, with the aim of achieving the performance of multiple tests on the material (Immunohistochemistry, real-time PCR, NGS) in order to fully check the molecular profile of your tumor (proteins, genes, histological Grading).

What happens if my sample is not sufficient?

In this case, and once sample enrichment manipulations have been exhausted, we contact your clinician to discuss alternative approaches in order to obtain the desired information to select the optimal treatment for you. Some examples:

Performing an alternative test (e.g. Immunohistochemistry instead of PCR, or choosing Next Generation Sequencing (NGS))
Performing Immunohistochemistry instead of FISH (Fluorescent In Situ Hybridization) and tubulin
Possible blood sampling instead of tissue testing (liquid biopsy)
Possible option to take a new biopsy or puncture